Ferroptosis-inducing agents compromise in vitro human islet viability and function article

Cell Death and Disease

Volumn 9, Issue 6, 2018, Pages

  Bruni, Antonio ^a,b   Pepper, Andrew R ^a   Pawlick, Rena L ^a   Gala Lopez, Boris ^c   Gamble, Anissa F ^a,b   Kin, Tatsuya ^a   Seeberger, Karen ^b   Korbutt, Gregory S ^b   Bornstein, Stefan R ^d   Linkermann, Andreas ^d   Shapiro, A M James ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; LACTATE DEHYDROGENASE; CARBOLINE DERIVATIVE; CHAC1 PROTEIN, HUMAN; CYCLOHEXYLAMINE DERIVATIVE; ERASTIN; FERROSTATIN-1; GAMMA GLUTAMYLCYCLOTRANSFERASE; GLUCOSE; IRON; MESSENGER RNA; PHENYLENEDIAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; RSL3 COMPOUND;

ANIMAL EXPERIMENT; ARTICLE; BLOOD GLUCOSE MONITORING; CELL DEATH; CELL FUNCTION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; FERROPTOSIS; GRAFT RECIPIENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; KIDNEY CAPSULE; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET; PRIORITY JOURNAL; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; TISSUE SURVIVAL;

ANIMALS; APOPTOSIS; CARBOLINES; CELLS, CULTURED; CYCLOHEXYLAMINES; DEFEROXAMINE; GAMMA-GLUTAMYLCYCLOTRANSFERASE; GLUCOSE; HUMANS; INSULIN SECRETION; IRON; ISLETS OF LANGERHANS; L-LACTATE DEHYDROGENASE; MICE, INBRED C57BL; PHENYLENEDIAMINES; PIPERAZINES; RNA, MESSENGER; TISSUE SURVIVAL;

EID: 85047634715     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/s41419-018-0506-0     Document Type: Article

References (37)

1. Bruni, A., Gala-Lopez, B., Pepper, A. R., Abualhassan, N. S. & Shapiro, A. J. Islet cell transplantation for the treatment of type 1 diabetes: Recent advances and future challenges. Diabetes Metab. Syndr. Obes. 7, 211-223 (2014).
2. Shapiro, A. M. et al. Islet transplantation in seven patientswith type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230-238 (2000).
3. Ryan, E. A. et al. Five-year follow-up after clinical islet transplantation. Diabetes 54, 2060-2069 (2005).
4. McCall, M. D. et al. Caspase inhibitor IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Transplantation 94, 30-35 (2012).
5. Davalli, A. M. et al. Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes 45, 1161-1167 (1996).
6. Biarnes, M. et al. Beta-cell death and mass in syngeneically transplanted islets exposed to short-And long-term hyperglycemia. Diabetes 51, 66-72 (2002).
7. Emamaullee, J. A., Stanton, L., Schur, C. & Shapiro, A. M. Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 56, 1289-1298 (2007).
8. Linkermann, A., Stockwell, B. R., Krautwald, S. & Anders, H. J. Regulated cell death and inflammation: An auto-Amplification loop causes organ failure. Nat. Rev. Immunol. 14, 759-767 (2014).
9. Linkermann, A. Nonapoptotic cell death in acute kidney injury and transplantation. Kidney Int. 89, 46-57 (2016).
10. Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311-320 (2015).
11. Wallach, D., Kang, T. B., Dillon, C. P. & Green, D. R. Programmed necrosis in inflammation: Toward identification of the effector molecules. Science 352, aaf2154 (2016).
12. Schwarznau, A. et al. IL-1beta receptor blockade protects islets against proinflammatory cytokine induced necrosis and apoptosis. J. Cell. Physiol. 220, 341-347 (2009).
13. SoRelle, J. A. et al. Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation. Diabetologia 56, 814-824 (2013).
14. Emamaullee, J. A. et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes 57, 1556-1566 (2008).
15. Batinic-Haberle, I. et al. SOD therapeutics: Latest insights into their structureactivity relationships and impact on the cellular redox-based signaling pathways. Antioxid. Redox Signal. 20, 2372-2415 (2014).
16. McCall, M. et al. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery 150, 48-55 (2011).
17. Linkermann, A. et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. USA 111, 16836-16841 (2014).
18. Dixon, S. J. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012).
19. Stockwell, B. R. et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273-285 (2017).
20. Yang, W. S. & Stockwell, B. R. Ferroptosis: Death by lipid peroxidation. Trends Cell Biol. 26, 165-176 (2016).
21. Dixon, S. J. & Stockwell, B. R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10, 9-17 (2014).
22. Reed, J. C. & Pellecchia, M. Ironing out cell death mechanisms. Cell 149, 963-965 (2012).
23. Bottino, R. et al. Preservation of human islet cell functional mass by antioxidative action of a novel SOD mimic compound. Diabetes 51, 2561-2567 (2002).
24. Bottino, R. et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 53, 2559-2568 (2004).
25. Skouta, R. et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136, 4551-4556 (2014).
26. Hennige, A. M., Lembert, N., Wahl, M. A. & Ammon, H. P. Oxidative stress increases potassium efflux from pancreatic islets by depletion of intracellular calcium stores. Free. Radic. Res. 33, 507-516 (2000).
27. Miwa, I., Ichimura, N., Sugiura, M., Hamada, Y. & Taniguchi, S. Inhibition of glucose-induced insulin secretion by 4-hydroxy-2-nonenal and other lipid peroxidation products. Endocrinology 141, 2767-2772 (2000).
28. Koulajian, K. et al. Overexpression of glutathione peroxidase 4 prevents betacell dysfunction induced by prolonged elevation of lipids in vivo. Am. J. Physiol. Endocrinol. Metab. 305, E254-E262 (2013).
29. Finkel, T. Oxygen radicals and signaling. Curr. Opin. Cell Biol. 10, 248-253 (1998).
30. do Amaral, A. S. et al. Glutathione ethyl ester supplementation during pancreatic islet isolation improves viability and transplant outcomes in a murine marginal islet mass model. PLoS ONE 8, e55288 (2013).
31. Jang, H. J. et al. Glutamine induces heat-shock protein-70 and glutathione expression and attenuates ischemic damage in rat islets. Transplant. Proc. 40, 2581-2584 (2008).
32. Avila, J. et al. Intra-ductal glutamine administration reduces oxidative injury during human pancreatic islet isolation. Am. J. Transplant. 5, 2830-2837 (2005).
33. Carobbio, S. et al. Insulin secretion profiles are modified by overexpression of glutamate dehydrogenase in pancreatic islets. Diabetologia 47, 266-276 (2004).
34. Li, C. et al. A signaling role of glutamine in insulin secretion. J. Biol. Chem. 279, 13393-13401 (2004).
35. Robertson, R. P., Harmon, J., Tran, P. O. & Poitout, V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53(Suppl 1), S119-S124 (2004).
36. Pepper, A. R. et al. Engraftment site and effectiveness of the pan-caspase inhibitor F573 to improve engraftment in mouse and human islet transplantation in mice. Transplantation 101, 2321-2329 (2017).
37. Kin, T. et al. Risk factors for islet loss during culture prior to transplantation. Transpl. Int. 21, 1029-1035 (2008).